- Home
- PULM vs SNSE Comparison
PULM vs SNSE Comparison
Compare PULM & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PULM | SNSE |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 13.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PULM | SNSE |
|---|---|---|
| Price | $2.60 | $9.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | 36.6K | ★ 74.5K |
| Earning Date | 10-16-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $134.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.15 | $5.00 |
| 52 Week High | $10.40 | $18.35 |
Technical Indicators
Market Signals| Indicator | PULM | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 45.75 |
| Support Level | $2.23 | $9.49 |
| Resistance Level | $2.70 | $12.00 |
| Average True Range (ATR) | 0.16 | 1.15 |
| MACD | 0.12 | -0.14 |
| Stochastic Oscillator | 88.78 | 33.89 |
Price Performance
Historical ComparisonAbout PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).